Statins as anti-inflammatory agents

Trends in Pharmacological Sciences

Volumn 23, Issue 10, 2002, Pages 482-487

  Weitz Schmidt, Gabriele ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; C REACTIVE PROTEIN; CD11B ANTIGEN; FLUINDOSTATIN; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LFA 703; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HUMAN; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SURVIVAL RATE;

EID: 0036805674     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)02077-1     Document Type: Review

References (46)

1. Istvan S.L., Deisenhofer J. Structural mechanisms for statin inhibition of HMG-CoA reductase. Science. 292:2001;1160-1164.
2. Corsini A., et al. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res. 31:1995;9-27.
3. Aoki T., et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneim.-Forsch. Drug Res. 47:1997;908-909.
4. Zhang F.L., Casey P.J. Protein prenylation: mechanisms and functional consequences. Annu. Rev. Biochem. 65:1996;241-269.
5. Dimmeler S., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J. Clin. Invest. 108:2001;391-397.
6. Llevadot J., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 108:2001;399-405.
7. Mundy G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1999;1946-1949.
8. Kwak B., et al. Statins as a newly recognized type of immunomodulator. Nat. Med. 6:2000;1399-1402.
9. Simes J., et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. Eur. Heart J. 23:2002;207-215.
10. The Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
11. Downs J.R., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J. Am. Med. Assoc. 279:1998;1615-1622.
12. Vaughan C.J., et al. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
13. Buchwald H., et al. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the program on the surgical control of the hyperlipidemias (POSCH). J. Am. Col. Cardiol. 26:1995;351-357.
14. Plutzky J., Ridker P.M. Statins for stroke. Circulation. 103:2001;348-350.
15. Kobashigawa J.A., et al. Effect of pravastatin on outcomes after cardiac transplantation. New Engl. J. Med. 333:1995;621-627.
16. Wenke K., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation. 96:1997;1398-1402.
17. Ridker P.M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. New Engl. J. Med. 344:2001;1959-1965.
18. Taubes G. Does inflammation cut to the heart of the matter? Science. 296:2002;242-245.
19. Diomede L., et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler. Thromb. Vasc. Biol. 21:2001;1327-1332.
20. Kimura M., et al. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 17:1997;1521-1526.
21. Stalker T.J., et al. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br. J. Pharmacol. 133:2001;406-412.
22. Sparrow C.P., et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 21:2001;115-121.
23. Maggard M.A., et al. Effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation. 65:1998;149-155.
24. Stanislaus R., et al. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci. Res. 66:2001;155-162.
25. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1994;301-314.
26. Pasceri V., et al. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2000;2165-2168.
27. Romano M., et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. 80:2000;1095-1100.
28. Yoshida M., et al. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro. Arterioscler. Thromb. Vasc. Biol. 21:2001;1165-1171.
29. Weber C., et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol. 30:1997;1212-1217.
30. Niwa S., et al. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int. J. Immunopharmacol. 18:1996;669-675.
31. Liu L., et al. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J. Biol. Chem. 274:1999;33334-33340.
32. Takeuchi S., et al. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of the rho GTPase in BAEC. Biochem. Biophys. Res. Commun. 269:2000;97-102.
33. Inoue I., et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phlox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci. 67:2000;863-876.
34. Ikeda U., Shimada K. Statins and monocytes. Lancet. 353:1999;2070.
35. Grip O., et al. Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes. Inflamm. Res. 51:2002;58-62.
36. Zelvyte I., et al. Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol. Res. 45:2002;147-154.
37. Laufs U., et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
38. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273:1998;24266-24271.
39. DeCaterina R., et al. Nitric oxide decreases cytokine-induced endothelial activation: NO selectively reduces endothelial expression of adhesion molecules and pro-inflammatory cytokines. J. Clin. Invest. 96:1995;60-68.
40. Martin G., et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J. Clin. Invest. 107:2001;1423-1432.
41. Ortego M., et al. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 147:1999;253-261.
42. Cammarano M.S., Minden A. Dbl and the Rho GTPases activate NFκB by IkB kinase (IKK)-dependent and IKK-independent pathways. J. Biol. Chem. 276:2001;25876-25882.
43. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 18:1999;6853-6866.
44. Kallen J., et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol. 292:1999;1-9.
45. Weitz-Schmidt G., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7:2001;687-692.
46. Lu C., et al. An isolated, surface-expressed I domain of the integrin αLβ2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond. Proc. Natl. Acad. Sci. U. S. A. 98:2001;2387-2392.